{"rewrite":{"id":"r_e182dbe15577fdef56c5f6bd","clusterId":"c_25d2cbacec5ee9217afa188b","slug":"metagen-therapeutics-raises-300-million-yen-in-series-b-extension","model":"deepseek-v4-1-flash","headline":"Metagen Therapeutics Raises 300 Million Yen In Series B Extension","summary":"Metagen Therapeutics, based in Tsuruoka City, Yamagata Prefecture, raised 300,036,750 yen from GLIN Impact Capital in the second close of its Series B extension round in September 2026. The round now totals 490 million yen, and cumulative funding reaches 7.14 billion yen. The funds go to clinical development of the oral FMT drug MGT-006 for ulcerative colitis and to other gut bacteria programs.","whyItMatters":"The raise extends a gut bacteria pipeline into clinical work for ulcerative colitis, gastrointestinal cancer, and Parkinson's disease, and it puts an impact fund behind a stool donation supply chain rather than a conventional drug candidate.","webCardHtml":"\u003cp\u003eThe second close adds GLIN Impact Capital as a subscriber through a third-party allotment of new shares. Metagen Therapeutics runs a supply chain that covers gut bacteria donor recruitment and screening, stool collection, and investigational drug manufacturing, based at a stool donation facility in Tsuruoka City, Yamagata Prefecture.\u003c/p\u003e\u003cp\u003eThe company is running Phase 1/Phase 2 trials of MGT-006, an oral FMT drug for ulcerative colitis, in Japan and the United States. It also points to clinical research on ulcerative colitis, gastrointestinal cancer, and Parkinson\u0026#39;s disease, and to MGT-001, MGT-007, and MGT-008 among the programs the proceeds will support.\u003c/p\u003e","blueskyPost":"MGT-006 is an oral FMT drug, so Metagen Therapeutics is funding its ulcerative colitis trial from a Series B extension rather than a fresh round. The second close of that extension brought in GLIN Impact Capital.","twitterPost":"Metagen Therapeutics is using a Series B extension, not a new round, to fund its oral FMT ulcerative colitis drug MGT-006.","threadsPost":"Metagen Therapeutics raised 300 million yen from GLIN Impact Capital, but the structure matters: it is a second close on a Series B extension, not a new round. The money goes to clinical development of MGT-006, an oral FMT drug for ulcerative colitis.","newsletterBlurb":"Metagen Therapeutics closed the second part of its Series B extension round with 300,036,750 yen from GLIN Impact Capital, bringing the round to 490 million yen and cumulative funding to 7.14 billion yen. The money goes toward clinical development of its gut bacteria-based drugs and medical technologies, including the oral FMT drug MGT-006 for ulcerative colitis. The company also operates its own stool donation and drug manufacturing supply chain in Tsuruoka City, Yamagata Prefecture.","attributionJson":"[{\"source\":\"ASCII.jp\",\"url\":\"https://ascii.jp/elem/000/004/437/4437305/?rss\",\"title\":\"Metagen Therapeutics Raises 300 Million Yen from Impact/ESG Investment Fund GLIN Impact Capital in Series B Extension Round, Cumulative Funding Tops 7.1 Billion Yen\"}]","lintFlagsJson":null,"lintHits":0,"costUsd":0,"inputTokens":4641,"outputTokens":654,"status":"published","repairAttempts":0,"nextRepairAt":null,"factsAttemptedAt":1791141267,"createdAt":"2026-10-04T19:12:03.000Z","publishedAt":"2026-10-04T19:13:25.000Z","updatedAt":"2026-10-04T19:13:25.000Z"},"cluster":{"id":"c_25d2cbacec5ee9217afa188b","canonicalTitle":"メタジェンセラピューティクス、シリーズBエクステンションラウンドでインパクト/ESG投資ファンド GLIN Impact Capital から3億円調達、累計調達額71億円以上に","representativeArticleId":"a_64967476c98526749b43ab61","sourceCount":1,"writtenSourceCount":1,"writeAttempts":0,"isSolo":true,"entitiesJson":"{\"anime_titles\":[],\"manga_titles\":[],\"work_titles\":[],\"studios\":[],\"people\":[],\"type\":\"business\",\"domain\":\"other\",\"is_roundup\":false}","contentType":"news","status":"published","firstSeenAt":"2026-09-25T04:00:00.000Z","lastSeenAt":"2026-09-25T04:00:00.000Z","updatedAt":"2026-10-04T19:13:20.000Z"},"attribution":[{"source":"ASCII.jp","url":"https://ascii.jp/elem/000/004/437/4437305/?rss","title":"メタジェンセラピューティクス、シリーズBエクステンションラウンドでインパクト/ESG投資ファンド GLIN Impact Capital から3億円調達、累計調達額71億円以上に"}],"entities":{"anime_titles":[],"manga_titles":[],"work_titles":[],"studios":[],"people":[],"type":"business","domain":"other","is_roundup":false},"keyFacts":null}